Harvard Bioscience (HBIO) Faces Strategic Evolution in Life Scie

FierceBiotechBiogen advances Alzheimer’s tau program despite midphase miss

PharmaVoiceFDA chief’s exit clouds already murky drug approvals

JEOLJEOL stock (JP3612800009): Medical equipment business sale to Sysmex marks strategic shift - AD HOC NEWS

Endpoints NewsBiogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

FierceBiotechAptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development

FierceBiotechRegenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy

CellTransplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models

Endpoints NewsRegenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval

Endpoints NewsBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Thermo FisherBetween Mettler-Toledo International and Thermo Fisher Scientific, Which Stock Looks Set to Break Out? - Trefis

AgilentAgilent Technologies (A) Valuation Check As New Biopharma Collaborations And Logic Analyzers Expand Growth Story - simplywall.st

PfizerShould you buy pharma stocks? Dr Reddy's, Pfizer - Target prices after Q4 results - Business Today